Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

類似資料

• Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
  著者:: Ebata, Takahiro, 等
  出版事項: (2019)
• First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
  著者:: Kondo, Shunsuke, 等
  出版事項: (2021)
• First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
  著者:: Koyama, Takafumi, 等
  出版事項: (2020)
• Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
  著者:: Shimomura, Akihiko, 等
  出版事項: (2017)
• Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
  著者:: Fujiwara, Yutaka, 等
  出版事項: (2020)